More on Questcor Pharmaceuticals (QCOR): Q4 beats on all counts as total revenue jumped 113%...

|By:, SA News Editor

More on Questcor Pharmaceuticals (QCOR): Q4 beats on all counts as total revenue jumped 113% Y/Y, primarily due to expanded Acthar prescriptions in the treatment of nephrotic syndrome as well as the treatment of MS relapses and infantile spasms. Net sales also benefited from the initiation of commercial activities focused on the use of Acthar in the treatment of rheumatology-related conditions. Despite the overall better numbers, the shares are -6.6% AH.